Skip Navigation

Annals of Oncology 2009 20(6):971; doi:10.1093/annonc/mdp299
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

in this issue

in this issue

The first 10% of the full text of this article appears below.


   Chemokine receptors in advanced breast cancer
 
Chemokines are a superfamily of small, cytokine-like proteins that induce cytoskeleton rearrangement, adhesion to endothelial cells, and directional migration. These secreted proteins act in a coordinated fashion with cell-surface proteins to direct the specific homing of various subsets of hematopoietic cells to specific anatomical sites. A CXC chemokine and its receptor, CXCR4, appear to be involved in the direction of metastatic organ . . . [Full Text of this Article]


   Two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer
 

   Hepatosplenic gamma-delta T-cell lymphoma
 

   Soft tissue sarcomas of the trunk wall
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications
N. Cabioglu, A. A. Sahin, P. Morandi, F. Meric-Bernstam, R. Islam, H. Y. Lin, C. D. Bucana, A. M. Gonzalez-Angulo, G. N. Hortobagyi, and M. Cristofanilli
Ann Oncol 2009 20: 1013-1019. [Abstract] [Full Text]  

A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC)
M. A. Socinski, M. N. Saleh, D. F. Trent, T. W. Dobbs, L. M. Zehngebot, M. A. Levine, R. Bordoni, and P. J. Stella
Ann Oncol 2009 20: 1068-1073. [Abstract] [Full Text]  

Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment
G. S. Falchook, F. Vega, N. H. Dang, F. Samaniego, M. A. Rodriguez, R. E. Champlin, C. Hosing, S. Verstovsek, and B. Pro
Ann Oncol 2009 20: 1080-1085. [Abstract] [Full Text]  

Soft tissue sarcomas of the trunk wall (STS-TW): a study of 343 patients from the French Sarcoma Group (FSG) database
S. Salas, B. Bui, E. Stoeckle, P. Terrier, D. Ranchere-Vince, F. Collin, A. Leroux, L. Guillou, J. J. Michels, M. Trassard, I. Valo, Y.-M. Robin, B. Marques, V. Brouste, and J.-M. Coindre
Ann Oncol 2009 20: 1127-1135. [Abstract] [Full Text]